Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
OBIO vs PTN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
OBIO Captures Overall Composite Edge (37.5 SELL vs 31.5 SELL), While PTN Leads 4–2 on Growth & Valuation Pillars
OBIO Overall Winner
6-Pillar Tally: OBIO 2 – 4 PTN
Matrix Metrics: OBIO 5 – 5 PTN
As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (37.5/100 SELL vs. 31.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.12 (N/M Forward P/E, -195.4% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin).
- Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.5/100 SELL vs. PTN 31.5/100 SELL) and 1.15β · 82% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both OBIO (37.5/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OBIO vs PTN
OBIO
Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
$7.12
-1.79% 1D
Market Cap
$570.6M
TTM Revenue
$31M
Forward P/E
N/M
Beta / 30D Vol
1.15β · 82% Vol
Unified Composite Score
37.5
SELL
Tech 15.0
Fund 36.0
Flow 55.0
Mom 44.0
Weinstein Technical Phase
Markup · Hold / add on dips
PTN
Palatin Technologies, Inc.
$6.12
-1.69% 1D
Market Cap
$11.1M
TTM Revenue
$13M
Forward P/E
42.9x
Beta / 30D Vol
0.87β · 106% Vol
Unified Composite Score
31.5
SELL
Tech 15.0
Fund 30.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (OBIO 2 – 4 PTN)
1. Valuation Multiples
PTN
Forward P/E
N/M
42.9x
Trailing P/E
N/M
42.9x
PEG Ratio
N/M
1.62x
EV / Revenue
18.6x
0.1x
2. Growth & Scale
OBIO
Revenue Growth (YoY)
-89.4%
-80.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$31M
$13M
Market Cap
$570.6M
$11.1M
3. Profitability & Quality
PTN
Gross Margin
99.6%
6.2%
Operating Margin
-195.4%
-65.7%
Net Profit Margin
-182.5%
-63.5%
Return on Equity (ROE)
-182.3%
-877.5%
4. Balance Sheet & Cash Flow
PTN
Cash Generation (TTM)
-$64M
-$15M
Cash Flow Margin
N/A
-113.6%
Net Cash / Leverage
$9.0M Net Debt (4.72x D/E)
$9.9M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OBIO
Options Structure Phase
BREAKOUT
UNCLASSIFIED
Current IV / %ile
70.8% (<1st %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
PTN
OpEx & R&D Intensity
N/A
71.9% of Rev ($9.5M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OBIO (5) vs PTN (5)| Institutional Metric | OBIO | PTN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $570.6M | $11.1M | OBIO | |
| Trailing P/E Ratio | N/M | 42.9x | PTN | |
| Forward P/E Ratio | N/M | 42.9x | PTN | |
| Revenue Growth (YoY) | -89.4% | -80.1% | PTN | |
| Operating Margin (TTM) | -195.4% | -65.7% | PTN | |
| Net Profit Margin | -182.5% | -63.5% | PTN | |
| Return on Equity (ROE) | -182.3% | -877.5% | OBIO | |
| 52-Week Range Position | 92% ($3–$7) | 6% ($5–$31) | OBIO | |
| Beta / 30D Volatility | 1.15β · 82% Vol | 0.87β · 106% Vol | OBIO | |
| Unified Institutional Score | 37.5 / 100 (SELL) | 31.5 / 100 (SELL) | OBIO | |
| Trailing 12M Revenue (USD) | $31M | $13M | Scale | |
| Gross Profit Margin (TTM) | 99.6% | 6.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 18.6x EV/Rev | 1.62x PEG · 0.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$64M ($9.0M Net Debt (4.72x D/E)) | -$15M ($9.9M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OBIO +28.9 pp
3M Horizon
OBIO +67.52 pp
6M Horizon
OBIO +138.7 pp
1Y Horizon
OBIO +113.62 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | PTN Revenue | OBIO Op. Margin | PTN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $70M | N/A | 38.6% | PTN |
| FY2019 | N/A | $60M | N/A | 59.3% | PTN |
| FY2020 | N/A | $0M | N/A | -20007.6% | PTN |
| FY2022 | $0M | $0M | -924.3% | -2491.6% | OBIO |
| FY2023 | $0M | $0M | -1866.2% | -668.7% | PTN |
| FY2024 | $0M | $0M | -2437.5% | -501.0% | PTN |
| FY2025 | $30M | N/A | -154.7% | N/A | OBIO |
| FY2026 | N/A | $10M | N/A | -65.7% | PTN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OBIO
BREAKOUT
Current IV
70.8%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PTN
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PTN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
71.9% of Rev ($9.5M)
90D Engineering Disclosures
0 Published
Investor FAQ OBIO vs PTN Key Questions & Quantitative Answers
As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over Palatin Technologies, Inc. (PTN) on higher Unified Composite conviction (37.5/100 SELL vs. 31.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while PTN wins 4–2 across the 6-pillar growth and valuation breakdown. OBIO trades at $7.12 (N/M Forward P/E, -195.4% operating margin) versus PTN at $6.12 (42.9x Forward P/E, -65.7% operating margin). Growth vs. Quality Trade-Off: OBIO earns the overall head-to-head edge with a stronger Unified Composite Score (37.5/100 SELL vs. PTN 31.5/100 SELL) and 1.15β · 82% Vol risk profile, whereas PTN leads top-line expansion (-80.1% YoY revenue growth, 1.62x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although OBIO compares more favorably head-to-head, both OBIO (37.5/100 SELL) and PTN (31.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), OBIO cumulative revenue shifted N/A while PTN shifted -85.7%. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.
PTN screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus PTN (-877.5% ROE) capital efficiency.
In options market volatility and institutional positioning, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 82% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PTN vs OBIO · Reverse Pair
OBIO vs OABI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal